Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

David D. Davidar net worth and biography

David Davidar Biography and Net Worth

Director of Globus Medical

David D. Davidar has served on our Board of Directors since 2003 and is a member of our Compensation Committee and our Nominating and Corporate Governance Committee. Mr. Davidar served as our Senior Vice President, Operations from January 2013 until March 2016 and as our Vice President, Operations from 2003 to January 2013.

Prior to joining Globus, Mr. Davidar served as the Executive Director of Highway Home, an assisted living facility, from 1995 to 2003. Mr. Davidar also served in a management capacity for Pizza Hut, Inc. from 1993 to 1995.

Mr. Davidar received a B.Com. in Commerce, Economics and Management from the University of Madras, a post-graduate diploma in Personnel Management at the Madras School of Social Work, and an M.B.A. from Bloomsburg University. Mr. Davidar’s role as one of our founders and his operational leadership of our Company have contributed significantly to our success and provided him with a deep familiarity with of its history and business. He brings valuable operational insight and managerial skill to our Board that qualify him to serve as one of our directors.

What is David D. Davidar's net worth?: The estimated net worth of David D. Davidar is at least $44.82 million as of October 16th, 2024. Mr. Davidar owns 536,275 shares of Globus Medical stock worth more than $44,821,865 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Davidar may own. Learn More about David D. Davidar's net worth.
How do I contact David D. Davidar?: The corporate mailing address for Mr. Davidar and other Globus Medical executives is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. Globus Medical can also be reached via phone at (610) 930-1800 and via email at [email protected]. Learn More on David D. Davidar's contact information.
Has David D. Davidar been buying or selling shares of Globus Medical?: During the last quarter, David D. Davidar has sold $2,251,200.00 in shares of Globus Medical stock. Most recently, David D. Davidar sold 30,000 shares of the business's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $75.04, for a transaction totalling $2,251,200.00. Following the completion of the sale, the director now directly owns 536,275 shares of the company's stock, valued at $40,242,076. Learn More on David D. Davidar's trading history.
Who are Globus Medical's active insiders?: Globus Medical's insider roster includes David Davidar (Director), David Demski (CEO), Robert Douglas (Director), Kelly Huller (SVP), Dan Lemaitre (Director), Leslie Norwalk (Director), Keith Pfeil (CFO), Ann Rhoads (Director), Daniel Scavilla (EVP), and James Tobin (Director). Learn More on Globus Medical's active insiders.
Are insiders buying or selling shares of Globus Medical?: During the last year, insiders at the medical device company sold shares 8 times. They sold a total of 204,890 shares worth more than $14,523,237.10. The most recent insider tranaction occured on November, 6th when CEO Daniel T. Scavilla sold 60,000 shares worth more than $4,801,200.00. Insiders at Globus Medical own 18.5% of the company. Learn More about insider trades at Globus Medical.
Information on this page was last updated on 11/6/2024.

David D. Davidar Insider Trading History at Globus Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/16/2024	Sell	30,000	$75.04	$2,251,200.00	536,275
5/8/2024	Sell	20,000	$65.00	$1,300,000.00	566,275
4/19/2022	Sell	31,500	$78.03	$2,457,945.00	601,275
11/24/2020	Sell	32,000	$60.00	$1,920,000.00	634,775
11/7/2019	Sell	38,000	$54.00	$2,052,000.00	666,775
8/16/2019	Sell	50,000	$49.33	$2,466,500.00	754,775
12/4/2017	Sell	55,383	$40.66	$2,251,872.78	752,236
7/5/2013	Sell	10,000	$17.15	$171,500.00
7/1/2013	Sell	20,000	$16.56	$331,200.00
6/26/2013	Sell	150,000	$16.71	$2,506,500.00
8/8/2012	Sell	166,885	$11.16	$1,862,436.60

David D. Davidar Buying and Selling Activity at Globus Medical

Globus Medical Company Overview

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Today's Range

Now: $83.58

$82.35

$83.91

50 Day Range

MA: $74.16

$69.33

$83.58

2 Week Range

Now: $83.58

$44.02

$84.87

Volume

1,038,264 shs

Average Volume

1,056,515 shs

Market Capitalization

$11.38 billion

P/E Ratio

124.75

Dividend Yield

N/A

Beta

1.17

This company will win the AI race

From Porter & Company | Ad